I2906

I2906 showed antimycobacterial and cytotoxic activity against mycobacterium tuberculosis. IC50 Value: Target: Antibacterial Under in vitro conditions, I2906 showed excellent antimycobacterial activities and low cytotoxicity. In a murine model infected with M. tuberculosis H37Rv, the reductions on bacterial loads of both lungs and spleen were statistically significant (p < 0.05) between I2906-treated mice and untreated controls after 4 weeks. Further, the colony-forming unit counts in the lungs were dramatically lower (p < 0.05) than that of isoniazid-treated mice by the addition of I2906 after 8 weeks. Moreover, survival rate was increased by I2906 treatment. For multidrug-resistant strain infection, bacterial counts were reduced significantly in the lungs and spleen due to I2906 treatment in comparison with data from untreated controls (p < 0.05) .

Product Specifications

CAS Number

[331963-29-2]

UNSPSC

12352005

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/I2906.html

Concentration

10mM

Purity

99.83

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(C(NNC(CCCCCCCCCCCC)=O)=O)=C(O)C2=CC=CC=C2N1CC

Molecular Formula

C25H37N3O4

Molecular Weight

443.58

References & Citations

[1]Lu, Jingning; Yue, Jun; Wu, Jing et al. In vitro and in vivo Activities of a New Lead Compound I2906 against Mycobacterium tuberculosis. Pharmacology (2010), 85 (6), 365-371.